Skip to main content
Premium Trial:

Request an Annual Quote

RBM, SMAF Discover Candidate Biomarkers for Spinal Muscular Atrophy

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rules-Based Medicine and the Spinal Muscular Atrophy Foundation today announced the discovery of candidate biomarkers, the first milestone in a program by the parties to develop a panel of protein biomarkers using RBM technology.

Using RBM's Multi-Analyte Profiling technology, biomarkers were found that "significantly differentiated" between disease and control groups and correlated with spinal muscular atrophy disease severity. The two parties are analyzing the results and plan to create a panel of biomarker assays to use in clinical trials to develop new treatments for the disease.

As part of the collaboration between the partners, RBM will also discover and confirm protein biomarkers previously identified from the multicenter Biomarkers for SMA clinical study sponsored by SMAF and conducted by BG Medicine.